Bristol-Myers Squibb (BMY): Opdivo/Yervoy Optionality Removed - Jefferies
Tweet Send to a Friend
Jefferies analyst, Jeffrey Holford, reiterated his Buy rating on shares of Bristol-Myers Squibb Co. (NYSE: BMY) after Bristol-Myers' management confirmed ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE